Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN-3694, Enzalutamide, and Pembrolizumab in mCRPC
NCT04471974Phase 2Active, not recruiting
- Sponsor
- Rahul Aggarwal
- Start
- Jan 2021
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ZEN3694 in castration-resistant prostate cancer (CRPC) (3 cohorts), sponsored by Rahul Aggarwal. Primary endpoint: Composite Response Rate up to 3 years. Started Jan 2021; status: active, not recruiting.
02
Drugs
ZEN3694
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT04471974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04471974.